Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Firms Ready To Repatriate Billions Once “JOBS” Bill Is Signed

This article was originally published in The Tan Sheet

Executive Summary

J&J intends to repatriate as much as $10 bil. held by foreign subsidiaries following President Bush's expected signing of the "JOBS" bill

You may also be interested in...



Repatriated Funds Should Not Be Used For Liability Costs – Congressman

The U.S. Treasury Department should clarify that pharmaceutical companies cannot use the tax repatriation provision of a recently enacted jobs bill to cover tort and liability expenses, House Ways & Means Health Subcommittee Ranking Member Pete Stark (D-Calif.) maintains

Repatriated Funds Should Not Be Used For Liability Costs – Congressman

The U.S. Treasury Department should clarify that pharmaceutical companies cannot use the tax repatriation provision of a recently enacted jobs bill to cover tort and liability expenses, House Ways & Means Health Subcommittee Ranking Member Pete Stark (D-Calif.) maintains

Repatriated Funds Should Not Be Used For Liability Costs – Congressman

The U.S. Treasury Department should clarify that pharmaceutical companies cannot use the tax repatriation provision of a recently enacted jobs bill to cover tort and liability expenses, House Ways & Means Health Subcommittee Ranking Member Pete Stark (D-Calif.) maintains

Related Content

Topics

UsernamePublicRestriction

Register

PS097412

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel